Global biosimilar monoclonal antibodies market is expected to grow with a CAGR of 55.2% over the forecast period of 2018-2024

Friday, December 14, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 13, 2018 /PRNewswire/ -- The report on global biosimilar monoclonal antibodies market provides qualitative and quantitative analysis for the period of 2016 to 2024.

Read the full report: https://www.reportlinker.com/p05627413 The report predicts the global biosimilar monoclonal antibodies market to grow with a CAGR of 55.2% over the forecast period of 2018-2024. The study on biosimilar monoclonal antibodies
market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific and RoW for the period of 2016 to 2024.The report on biosimilar monoclonal antibodies market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global biosimilar monoclonal antibodies market over the period of 2016 to 2024. Moreover, the report is a collective presentation of primary and secondary research findings.Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global biosimilar monoclonal antibodies market over the period of 2016 to 2024. Further, IGR- Growth Matrix given in the report brings an insight into the investment areas that existing or new market players can consider.Research MethodologyA) Primary ResearchOur primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through1. Key Opinion Leaders associated with Infinium Global Research2. Internal and External subject matter experts3. Professionals and participants from LinkedIn, Hoovers, Factiva and BloggersOur primary research respondents typically include1. Executives working with leading companies in the market under review2. Product/brand/marketing managers3. CXO level executives4. Regional/zonal/ country managers5. Vice President level executives.B) Secondary ResearchSecondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.The secondary sources of the data typically include1. Company reports and publications2. Government/institutional publications3. Trade and associations journals4. Databases such as WTO, OECD, World Bank, and among others.5. Websites and publications by research agenciesReport Findings1) Drivers• Rising Demand for Biosimilar Drugs Owing to their Cost Effectiveness• Prevalence of Chronic Diseases among Geriatric Population2) Restraints• Unfavorable Government Regulations in Developed Economies• High Cost Associated With Manufacturing Process3) Opportunities• Growing Collaboration among the Local PlayersSegment CoveredThe global biosimilar monoclonal antibodies market is segmented on the basis of application and drug class.Global Biosimilar Monoclonal Antibodies Market by Application• Diagnostic Applicationso MAbs in Biochemical Analysis• Pregnancy• Cancers• Hormonal disorders• Infectious diseaseso MAbs in Diagnostic Imaging• Cardiovascular diseases• Deep vein thrombosis (DVT)• Atherosclerosis• Cancers• Bacterial infections• Therapeutic Applicationso MAbs as Direct Therapeutic Agentso MAbs as Targeting Agents in Therapy• Protein PurificationGlobal Biosimilar Monoclonal Antibodies Market by Drug Class• Rituximab• Infliximab• Abciximab• Trastuzumab• Adalimumab• BevacizumabCompany Profiles• Pfizer Inc.• Novartis AG• Reliance Life Sciences• Allergan plc• Coherus BioSciences, Inc.• Biocon• Boehringer Ingelheim GmbH• BioXpress Therapeutics SA• Intas Pharmaceuticals Limited• Genor BioPharma Co. LtdWhat does this report deliver?1. Comprehensive analysis of global as well as regional markets of biosimilar monoclonal antibodies market.2. Complete coverage of all the segments in biosimilar monoclonal antibodies market to analyze the trends, developments in the global market and forecast of market size up to 2024.3. Comprehensive analysis of the companies operating in global biosimilar monoclonal antibodies market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.Read the full report: https://www.reportlinker.com/p05627413 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/global-biosimilar-monoclonal-antibodies-market-is-expected-to-grow-with-a-cagr-of-55-2-over-the-forecast-period-of-2018-2024--300765207.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store